Re:Antiviral Molnupiravir Reduces Risk of Hospitalization/De...
by nradov on Friday October 01, 2021 @05:17PM
(#28723476)
That study you linked isn't relevant to my point. The question is whether the initial viral dose at the point of infection is correlated with symptom severity later in the disease course. That remains unknown. The study looked at the relation between current viral load and symptoms after infection, which is an entirely separate issue.
https://www.nature.com/articles/s41467-020-19057-5
> It's a plausible hypothesis
It's extremely plausible, and been demonstrated before in influenza, poxviruses, and other viruses. The human challenge trials necessary to prove a dose-dependent relationship between fall height and lethality haven't been conducted, either, but we have sufficient evidence from longitudinal and natural experiments to draw firm conclusions.